SBSteven J. Burden

Steven J. Burden

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Steven J. Burden has a total of 126 co-authors. Here are the top co-authors by number of shared publications:

  • Julien Oury

    7 shared publications
  • Natalie Kim

    Molecular Neurobiology Program, Helen L. and Martin S. Kimmel Center for Biology and Medicine at the Skirball Institute of Biomolecular Medicine, New York University Medical School, New York, New York 10016, USA

    5 shared publications
  • Norihiro Yumoto

    Skirball Institute of Biomolecular Medicine, NYU Medical School, New York, New York 10016

    4 shared publications
  • Roeland Vanhauwaert

    Department of Neurosurgery, Stanford University School of Medicine, USA

    4 shared publications
  • Wei Zhang

    Helen L. and Martin S. Kimmel Center for Biology and Medicine at the Skirball Institute of Biomolecular Medicine, NYU Grossman School of Medicine, New York, USA

    4 shared publications
  • Andrea M. Gomez

    Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, USA

    3 shared publications

Latest Publications

  • Open Access

    Cytoplasmic region of beta-dystroglycan is essential for postsynaptic maturation and neuromuscular function in mice

    by Jeffrey M. Hord, Rolf Turk, Hajime Kusano, Erik P. Rader, Sarah Burns, Zeita Gastel, Sally J. Prouty, Liping Yu, Steven J. Burden, Kevin P. Campbell

    The dystrophin–glycoprotein complex (DGC) provides structural integrity to the sarcolemma, and disruption of the DGC leads to muscular dystrophy. A core member of the DGC is dystroglycan (DG), which binds to extracellular ligands via α-DG and intracellular cytoskeleton via β-DG. Mutations in DAG1 or genes involved in the posttranslational processing of DG lead to a subset of neuromuscular diseases referred to as dystroglycanopathies. The importance of the α-DG extracellular interactions is well established; however, little is known about the significance of the β-DG intracellular interactions. Here, we investigate the importance of intracellular β-DG in neuromuscular health. Using a mouse that lacks a large intracellular region of β-DG (residues 777 to 893), we show that the deletion of cytoplasmic β-DG leads to skeletal muscle pathology accompanied by postsynaptic disruption. Our data show that within the specialized neuromuscular junction (NMJ), cytoplasmic β-DG is necessary for the localization of utrophin and rapsyn, and clustering of acetylcholine receptors. Moreover, we provide evidence that the postsynaptic abnormalities contribute to neuromuscular dysfunction in mice lacking the cytoplasmic region of β-DG. Further, using a mouse model that only lacks the C-terminal tail (residues 879 to 893) of β-DG, we demonstrate that skeletal muscle and NMJ health rely on β-DG residues 777 to 878. Together, our mouse models suggest that deletion of the cytodomain of β-DG surprisingly results in very severe neuromuscular pathophysiology in mice. Our results identify β-DG as a critical player in shaping and maintaining neuromuscular synapse architecture in vivo, thus further defining the molecular mechanisms underlying neuromuscular health.


  • Open Access

    Gene-specific response to MuSK agonist antibody in the treatment of Congenital Myasthenic Syndromes

    by Kelly Ho, Ofosu Adjei-Afriyie, Ricardo Carmona-Martinez, Rohan Ray, Daniel O’neil, Joshua Zeldin, Julien Oury, Lieselot De Clercq, Steven J. Burden, Bernhardt Vankerckhoven, et al.

    Congenital myasthenic syndromes (CMS) are a group of rare disorders characterized by fatigable muscle weakness and caused by impaired neuromuscular junction (NMJ) function. CMS symptoms are highly variable, but can be detrimental and lead to death. There are over 40 different genetic subtypes, including Agrn- CMS and ColQ- CMS. Agrn encodes for neural AGRIN, which is released from the nerve terminal and triggers muscle-specific kinase phosphorylation (pMuSK). pMuSK is essential for NMJ development and maintenance, thus AGRIN deficiency causes NMJ impairment. ColQ encodes for collagenous subunit Q (ColQ), which anchors acetylcholinesterase and stabilizes MuSK. As a result, ColQ deficiency results in NMJ degeneration from prolonged transmission signals and decreased pMuSK. Current treatments for Agrn- CMS and ColQ- CMS are limited, highlighting the importance of finding more efficient therapies. Recently, a MuSK agonist antibody with high affinity for the Frizzled-like domain showed remarkable rescue of a Dok7 -CMS mouse model. We hypothesized a similar antibody could benefit Agrn- and ColQ- CMS mouse models. Agrn- CMS mice were treated at postnatal day 5 (P5), P15 and P35, and ColQ- CMS mice were treated weekly from P22 to P57. In Agrn- CMS mice, 3B2 treatment rescued survival, bodyweight, fibre type switching and pMuSK levels, and improved grip strength and NMJ morphology. In ColQ- CMS mice, 3B2 treatment was unable to rescue deficits observed. Our findings suggest that MuSK agonists may benefit patients with Agrn -CMS, which should be tested in clinical trials. Our study emphasizes that effective CMS treatment is gene-dependent and relies on an accurate genetic diagnosis.

  • ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndrome

    by Roeland Vanhauwaert, Julien Oury, Bernhardt Vankerckhoven, Christophe Steyaert, Stine Marie Jensen, Dana L. E. Vergoossen, Christa Kneip, Leah Santana, Jamie L. Lim, Jaap J. Plomp, et al.

    Muscle-specific kinase (MuSK) is essential for the formation, function, and preservation of neuromuscular synapses. Activation of MuSK by a MuSK agonist antibody may stabilize or improve the function of the neuromuscular junction (NMJ) in patients with disorders of the NMJ, such as congenital myasthenia (CM). Here, we generated and characterized ARGX-119, a first-in-class humanized agonist monoclonal antibody specific for MuSK, that is being developed for treatment of patients with neuromuscular diseases. We performed in vitro ligand-binding assays to show that ARGX-119 binds with high affinity to the Frizzled-like domain of human, nonhuman primate, rat, and mouse MuSK, without off-target binding, making it suitable for clinical development. Within the Fc region, ARGX-119 harbors L234A and L235A mutations to diminish potential immune-activating effector functions. Its mode of action is to activate MuSK, without interfering with its natural ligand neural Agrin, and cluster acetylcholine receptors in a dose-dependent manner, thereby stabilizing neuromuscular function. In a mouse model of DOK7 CM, ARGX-119 prevented early postnatal lethality and reversed disease relapse in adult Dok7 CM mice by restoring neuromuscular function and reducing muscle weakness and fatigability in a dose-dependent manner. Pharmacokinetic studies in nonhuman primates, rats, and mice revealed a nonlinear PK behavior of ARGX-119, indicative of target-mediated drug disposition and in vivo target engagement. On the basis of this proof-of-concept study, ARGX-119 has the potential to alleviate neuromuscular diseases hallmarked by impaired neuromuscular synaptic function, warranting further clinical development.


  • Open Access

    Agonist antibody to MuSK protects mice from MuSK myasthenia gravis

    by Julien Oury, Begona Gamallo-Lana, Leah Santana, Christophe Steyaert, Dana L. E. Vergoossen, Adam C. Mar, Bernhardt Vankerckhoven, Karen Silence, Roeland Vanhauwaert, Maartje G. Huijbers, et al.

    Myasthenia gravis (MG) is a chronic and severe disease of the skeletal neuromuscular junction (NMJ) in which the effects of neurotransmitters are attenuated, leading to muscle weakness. In the most common forms of autoimmune MG, antibodies attack components of the postsynaptic membrane, including the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK). MuSK, a master regulator of NMJ development, associates with the low-density lipoprotein-related receptor 4 (Lrp4) to form the signaling receptor for neuronal Agrin, a nerve-derived synaptic organizer. Pathogenic antibodies to MuSK interfere with binding between MuSK and Lrp4, inhibiting the differentiation and maintenance of the NMJ. MuSK MG can be debilitating and refractory to treatments that are effective for AChR MG. We show here that recombinant antibodies, derived from MuSK MG patients, cause severe neuromuscular disease in mice. The disease can be prevented by a MuSK agonist antibody, presented either prophylactically or after disease onset. These findings suggest a therapeutic alternative to generalized immunosuppression for treating MuSK MG by selectively and directly targeting the disease mechanism.


  • Open Access

    ARGX-119, a therapeutic agonist antibody targeting MuSK

    by Roeland Vanhauwaert, Julien Oury, Bernhardt Vankerckhoven, Christophe Steyaert, Stine Marie Jensen, Dana L.E. Vergoossen, Christa Kneip, Leah Santana, Jamie L. Lim, Jaap J. Plomp, et al.

    ARGX-119 is a novel, humanized, agonist monoclonal SIMPLE Antibody™ specific for muscle-specific kinase (MuSK) that is being developed for treatment of patients with neuromuscular diseases. ARGX-119 is the first monoclonal antibody (mAb) that binds with high affinity to the Frizzled-like domain of human, non-human primate, rat and mouse MuSK, without off-target binding, making it suitable for clinical development. Within the Fc-region, ARGX-119 harbors L234A, L235A mutations to diminish potential immune-activating effector functions. Its mode-of-action is to activate MuSK without interfering with its natural ligand neural Agrin, and cluster acetylcholine receptors (AChRs) in a dose-dependent manner, thereby stabilizing neuromuscular function. In a mouse model for DOK7 congenital myasthenia (CM), ARGX-119 prevented early postnatal lethality and reversed disease relapse by restoring neuromuscular function and reducing muscle weakness and fatigability in a dose-dependent manner. Pharmacokinetic (PK) studies in non-human primates, rats and mice revealed non-linear PK behavior of ARGX-119, indicative of target-mediated-drug disposition (TMDD) and in vivo target engagement. Instability of neuromuscular synapses contributes to symptoms in many neuromuscular diseases for example congenital myasthenia (CM), amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). ARGX-119 is a novel, first-in-class MuSK agonist mAb in clinical development. Based on this proof-of-concept study, it has the potential to alleviate neuromuscular diseases hallmarked by impaired neuromuscular synaptic function. One sentence summary: ARGX-119 is a novel first-in-class MuSK agonist monoclonal antibody in clinical development for treatment of neuromuscular diseases.


  • Building, Breaking, and Repairing Neuromuscular Synapses

    by Ruth Herbst, Maartje G. Huijbers, Julien Oury, Steven J. Burden

    A coordinated and complex interplay of signals between motor neurons, skeletal muscle cells, and Schwann cells controls the formation and maintenance of neuromuscular synapses. Deficits in the signaling pathway for building synapses, caused by mutations in critical genes or autoantibodies against key proteins, are responsible for several neuromuscular diseases, which cause muscle weakness and fatigue. Here, we describe the role that four key genes, Agrin, Lrp4, MuSK, and Dok7, play in this signaling pathway, how an understanding of their mechanisms of action has led to an understanding of several neuromuscular diseases, and how this knowledge has contributed to emerging therapies for treating neuromuscular diseases.


  • Open Access

    Mechanism of disease and therapeutic rescue of Dok7 congenital myasthenia

    by Julien Oury, Wei Zhang, Nadia Leloup, Akiko Koide, Alexis D. Corrado, Gayatri Ketavarapu, Takamitsu Hattori, Shohei Koide, Steven J. Burden

    Congenital myasthenia (CM) is a devastating neuromuscular disease, and mutations in DOK7, an adaptor protein that is crucial for forming and maintaining neuromuscular synapses, are a major cause of CM1,2. The most common disease-causing mutation (DOK71124_1127 dup) truncates DOK7 and leads to the loss of two tyrosine residues that are phosphorylated and recruit CRK proteins, which are important for anchoring acetylcholine receptors at synapses. Here we describe a mouse model of this common form of CM (Dok7CM mice) and a mouse with point mutations in the two tyrosine residues (Dok72YF). We show that Dok7CM mice had severe deficits in neuromuscular synapse formation that caused neonatal lethality. Unexpectedly, these deficits were due to a severe deficiency in phosphorylation and activation of muscle-specific kinase (MUSK) rather than a deficiency in DOK7 tyrosine phosphorylation. We developed agonist antibodies against MUSK and show that these antibodies restored neuromuscular synapse formation and prevented neonatal lethality and late-onset disease in Dok7CM mice. These findings identify an unexpected cause for disease and a potential therapy for both DOK7 CM and other forms of CM caused by mutations in AGRIN, LRP4 or MUSK, and illustrate the potential of targeted therapy to rescue congenital lethality.


  • Open Access

    Affinity maturation is required for pathogenic monovalent IgG4 autoantibody development in myasthenia gravis

    by Miriam L. Fichtner, Casey Vieni, Rachel L. Redler, Ljuvica Kolich, Ruoyi Jiang, Kazushiro Takata, Panos Stathopoulos, Pablo A. Suarez, Richard J. Nowak, Steven J. Burden, et al.

    Pathogenic muscle-specific tyrosine kinase (MuSK)–specific IgG4 autoantibodies in autoimmune myasthenia gravis (MG) are functionally monovalent as a result of Fab-arm exchange. The development of these unique autoantibodies is not well understood. We examined MG patient–derived monoclonal autoantibodies (mAbs), their corresponding germline-encoded unmutated common ancestors (UCAs), and monovalent antigen-binding fragments (Fabs) to investigate how affinity maturation contributes to binding and immunopathology. Mature mAbs, UCA mAbs, and mature monovalent Fabs bound to MuSK and demonstrated pathogenic capacity. However, monovalent UCA Fabs bound to MuSK but did not have measurable pathogenic capacity. Affinity of the UCA Fabs for MuSK was 100-fold lower than the subnanomolar affinity of the mature Fabs. Crystal structures of two Fabs revealed how mutations acquired during affinity maturation may contribute to increased MuSK-binding affinity. These findings indicate that the autoantigen drives autoimmunity in MuSK MG through the accumulation of somatic mutations such that monovalent IgG4 Fab-arm–exchanged autoantibodies reach a high-affinity threshold required for pathogenic capacity.


  • Open Access

    Vezatin is required for the maturation of the neuromuscular synapse

    by Natasha Koppel, Matthew B. Friese, Helene L. Cardasis, Thomas A. Neubert, Steven J. Burden

    Key genes, such as Agrin, Lrp4, and MuSK, are required for the initial formation, subsequent maturation, and long-term stabilization of mammalian neuromuscular synapses. Additional molecules are thought to function selectively during the evolution and stabilization of these synapses, but these molecular players are largely unknown. Here, we used mass spectrometry to identify vezatin, a two-pass transmembrane protein, as an acetylcholine receptor (AChR)–associated protein, and we provide evidence that vezatin binds directly to AChRs. We show that vezatin is dispensable for the formation of synapses but plays a later role in the emergence of a topologically complex and branched shape of the synapse, as well as the stabilization of AChRs. In addition, neuromuscular synapses in vezatin mutant mice display premature signs of deterioration, normally found only during aging. Thus, vezatin has a selective role in the structural elaboration and postnatal maturation of murine neuromuscular synapses.


  • Open Access

    MACF1 links Rapsyn to microtubule- and actin-binding proteins to maintain neuromuscular synapses

    by Julien Oury, Yun Liu, Ana Töpf, Slobodanka Todorovic, Esthelle Hoedt, Veeramani Preethish-Kumar, Thomas A. Neubert, Weichun Lin, Hanns Lochmüller, Steven J. Burden

    Complex mechanisms are required to form neuromuscular synapses, direct their subsequent maturation, and maintain the synapse throughout life. Transcriptional and post-translational pathways play important roles in synaptic differentiation and direct the accumulation of the neurotransmitter receptors, acetylcholine receptors (AChRs), to the postsynaptic membrane, ensuring for reliable synaptic transmission. Rapsyn, an intracellular peripheral membrane protein that binds AChRs, is essential for synaptic differentiation, but how Rapsyn acts is poorly understood. We screened for proteins that coisolate with AChRs in a Rapsyn-dependent manner and show that microtubule actin cross linking factor 1 (MACF1), a scaffolding protein with binding sites for microtubules (MT) and actin, is concentrated at neuromuscular synapses, where it binds Rapsyn and serves as a synaptic organizer for MT-associated proteins, EB1 and MAP1b, and the actin-associated protein, Vinculin. MACF1 plays an important role in maintaining synaptic differentiation and efficient synaptic transmission in mice, and variants in MACF1 are associated with congenital myasthenia in humans.